All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Momelotinib vs ruxolitinib in patients with MF by baseline hemoglobin levels: Exploratory post hoc analysis from SIMPLIFY-1
Bookmark this article
|
The phase III SIMPLIFY-1 trial (NCT01969838) evaluated momelotinib vs ruxolitinib in Janus kinase inhibitor (JAKi)-naïve patients with myelofibrosis (MF).1 The MPN Hub previously reported long-term outcomes and updated results from this trial. An exploratory post hoc analysis from this trial assessed the benefits of momelotinib in subgroups defined by baseline hemoglobin levels (moderate/severe anemia, <10 g/dL; mild anemia, ≥10 to <12 g/dL; nonanemic, ≥12 g/dL).1 Results from this analysis were published in Leukemia & Lymphoma by Gupta et al.1 |
| Key learnings1 |
| Momelotinib demonstrated an advantage in transfusion independence rates at Week 24 over ruxolitinib in anemic patients, particularly in the mildly anemic subgroup (moderate/severe anemia, 46.5% vs 26.6%; mild anemia, 80.8% vs 50.7%), while the benefit was less clear in nonanemic patients (78.6% vs 86.8%). |
| The safety profile of momelotinib remained consistent across the subgroups, with fewer key hematologic treatment-emergent adverse events, including anemia and thrombocytopenia, compared with ruxolitinib, potentially allowing for full-dose administration in more patients. |
| Momelotinib provided similar splenic response rates at Week 24 to ruxolitinib across all subgroups, but with the added benefit of better anemia management, highlighting its comprehensive efficacy in treating patients with MF. |
| These findings are consistent with the overall patient population of the SIMPLIFY-1 trial and suggest that momelotinib is a viable treatment option for patients with MF regardless of baseline hemoglobin levels, as it offers a balanced approach to managing anemia without compromising on spleen or symptom benefits. |
- Gupta V, Oh S, Devos T, et al. Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial. Leuk Lymphoma. 2024;65(7):965-977. DOI: 1080/10428194.2024.2328800
Your opinion matters
26 votes - 22 days left ...
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox